- <![CDATA[Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors ]]><![CDATA[Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors. ]]>onclive · 2mo ago↗ source
- Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech,…Endpoints · 2mo ago↗ source
- <![CDATA[Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD ]]><![CDATA[Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.]]>